id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-312997-wcqdksfg	Favresse, Julien	Clinical performance of the Elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies	2020-06-02		.txt	text/plain	651	44	47	In the context of COVID-19, a wide range of serology immunoassays with different SARS-CoV-2 antigen recognition and antibody specificity have been developed to complement RT-PCR assays [1] . This study is the first to report the external validation of a new electrochemiluminescent immunoassay (ECLIA) test, the Elecsys anti-SARS-CoV-2 from Roche Diagnostics ® . This retrospective study was conducted from May 6 to 12, 2020 at the clinical biology Analyses of serum samples obtained 28 days or more after symptom onset provided a sensitivity of 96.7% (95%CI: 82.8-99.9%) and 100% (95%CI: 88.9-100%) with the manufacturer and the optimized cut-off, respectively (Figure 1) . The optimal ROC cut-off showed excellent clinical performance 14 days or more following RT-PCR positivity or following the onset of COVID-19 symptoms.	./cache/cord-312997-wcqdksfg.txt	./txt/cord-312997-wcqdksfg.txt